Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation

To determine the safety, efficacy, and PK profile of intravenous busulfan (Bu) in the context of a Bu and cyclophosphamide (IVBuCy) preparative regimen in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

[1]  W. Tse,et al.  Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant , 2009, Bone Marrow Transplantation.

[2]  D. Rondelli.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.

[3]  Takeyuki Sato,et al.  Population Pharmacokinetics of Oral Busulfan in Young Japanese Children Before Hematopoietic Stem Cell Transplantation , 2008, Therapeutic drug monitoring.

[4]  G. Vassal,et al.  Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring , 2007, Cancer Chemotherapy and Pharmacology.

[5]  J. Gobburu,et al.  Population Pharmacokinetic–Based Dosing of Intravenous Busulfan in Pediatric Patients , 2007, Journal of clinical pharmacology.

[6]  Moo-Song Lee,et al.  Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation , 2005, Annals of Hematology.

[7]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[8]  L. Nguyen,et al.  I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients , 2004, Bone Marrow Transplantation.

[9]  H. Deeg,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.

[10]  Y. Théorêt,et al.  Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results , 2003, Bone Marrow Transplantation.

[11]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[12]  J. Radich,et al.  HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. , 2003, Blood.

[13]  L. Dupuis,et al.  Retrospective appraisal of busulfan dose adjustment in children , 2003, Bone Marrow Transplantation.

[14]  A. Westfall,et al.  A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  P. Thall,et al.  Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  D. Glidden,et al.  Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation , 2001, Bone Marrow Transplantation.

[17]  B. Andersson,et al.  Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  T. Madden,et al.  Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies , 2000, Bone Marrow Transplantation.

[19]  B. Bostrom,et al.  An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease , 2000, Bone Marrow Transplantation.

[20]  J. Wingard,et al.  Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy) , 2000, Bone Marrow Transplantation.

[21]  J. Slattery,et al.  Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. , 1998, Therapeutic drug monitoring.

[22]  P. Ljungman,et al.  High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients , 1997, Bone Marrow Transplantation.

[23]  M. Karlsson,et al.  Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. , 1996, Bone marrow transplantation.

[24]  J. Wingard,et al.  Association of busulfan area under the curve with veno-occlusive disease following BMT. , 1996, Bone marrow transplantation.

[25]  F. Appelbaum,et al.  Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. , 1995, Bone marrow transplantation.

[26]  G. Vassal,et al.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation , 1995, Cancer Chemotherapy and Pharmacology.

[27]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[28]  T. Madden,et al.  Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Grochow,et al.  Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. , 1992, Blood.

[30]  G. Vassal,et al.  Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? , 1992, Blood.

[31]  K. Weinberg,et al.  Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. , 1991, Bone marrow transplantation.

[32]  L. Grochow,et al.  Busulfan disposition in children. , 1990, Blood.

[33]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[34]  P. Porter.  Effects of murine erythroleukemia inducers on mouse erythroid colony formation in culture. , 1979, Differentiation; research in biological diversity.

[35]  Y. Ikawa,et al.  Early decrease in hyaluronidase-sensitive cell surface charge during the differentiation of Friend erythroleukemic cells by dimethyl sulfoxide. , 1979, Cancer research.

[36]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[37]  E. Mancall,et al.  A phase I study of dimethylacetamide. , 1962, Cancer chemotherapy reports.

[38]  B. Andersson,et al.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy , 2009, Cancer Chemotherapy and Pharmacology.

[39]  G. Vassal,et al.  Pharmacokinetics of high-dose busulfan in children , 2004, Cancer Chemotherapy and Pharmacology.

[40]  L. Grochow,et al.  Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation , 2004, Cancer Chemotherapy and Pharmacology.

[41]  S. Eksborg,et al.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults , 2004, European Journal of Clinical Pharmacology.

[42]  P. Ljungman,et al.  Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology , 2004, Cancer Chemotherapy and Pharmacology.

[43]  G. Vassal,et al.  Is 600 mg / m 2 the Appropriate Dosage of Busulfan in Children Undergoing Bone Marrow Transplantation ? , 2003 .

[44]  P F Thall,et al.  New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Shaw,et al.  Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. , 1994, Blood.

[46]  J. Koeller,et al.  Phase I trial of PCNU administered by 5-day courses. , 1981, Cancer treatment reports.